Compounded medications are mixed by a specialized pharmacist and formulated for an individual patient
The primary human-use benefits proposed in preclinical (animal) studies include: Accelerated tendon and ligament repair Enhanced muscle healing following injury Reduced inflammation at injury sites Improved bone fracture healing Gastroprotective effects Potential neuroprotective properties How It Works Angiogenesis and VEGF Upregulation One of BPC-157's best-documented mechanisms involves stimulating angiogenesis the formation of new blood vessels
This mechanism has been linked with reduced fat cell size , increased insulin sensitivity , and improved overall metabolic efficiency
Confusing mg and mcg: This is the single most common dosing error

It is classified as a research chemical, meaning: It cannot be legally marketed as a drug or supplement It is not recognized as "Generally Recognized as Safe" (GRAS) No New Drug Application (NDA) has been submitted It has not undergone the formal FDA approval process Research Chemical Status BPC-157 is available for purchase as a "research chemical" in most jurisdictions, with important caveats: Sold for "research purposes only" Not for human consumption (legally) No quality standards enforced by regulatory agencies Purity and identity depend entirely on supplier integrity International Regulations Regulatory status varies by country: United States : Research chemical, not approved for human use European Union : Not approved, status varies by member state Canada : Not approved for human use, research chemical Australia : Not approved, TGA Category 4 substance United Kingdom : Not approved for human use Sports and Competition BPC-157 is not specifically listed on the World Anti-Doping Agency (WADA) prohibited list, unlike TB-500
